Patented synthesis displaying all disease diagnostics
Aptenia has developed and patented an original, reliable chemical synthesis route, to yield a stable and modular scaffold based on an organometallic group called "titanocene". Titanocenes are known to display insufficient efficacy to anti-cancer drugs in a clinical setting. Yet through Aptenia a profound knowledge has been generated on their clinical safety and their metabolites in humans with no adverse effects. Aptenia's customers are qualified professionals in hospitals and the patients. Producing a fast, real time, qualitative display for hospital staff and patients in addition to delivering real-time solutions.